HER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agent
Open Access
- 24 March 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (3) , e18103
Abstract
The application of magnetic resonance imaging (MRI) to non-invasively assess disease biomarkers has been hampered by the lack of desired contrast agents with high relaxivity, targeting capability, and optimized pharmacokinetics. We have developed a novel MR imaging probe targeting to HER2, a biomarker for various cancer types and a drug target for anti-cancer therapies. This multimodal HER20targeted MR imaging probe integrates a de novo designed protein contrast agent with a high affinity HER2 affibody and a near IR fluorescent dye. Our probe can differentially monitor tumors with different expression levels of HER2 in both human cell lines and xenograft mice models. In addition to its 100-fold higher dose efficiency compared to clinically approved non-targeting contrast agent DTPA, our developed agent also exhibits advantages in crossing the endothelial boundary, tissue distribution, and tumor tissue retention over reported contrast agents as demonstrated by even distribution of the imaging probe across the entire tumor mass. This contrast agent will provide a powerful tool for quantitative assessment of molecular markers, and improved resolution for diagnosis, prognosis and drug discovery.Keywords
This publication has 29 references indexed in Scilit:
- The HER2 testing conundrumNature Biotechnology, 2010
- Towards Targeted MRI: New MRI Contrast Agents for Sialic Acid DetectionChemistry – A European Journal, 2004
- MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agentsMagnetic Resonance Imaging, 2004
- Selection and characterization of HER2/neu-binding affibody ligandsProtein Engineering, Design and Selection, 2004
- Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRIMagnetic Resonance in Medicine, 2004
- Tissue-specific MR contrast agentsEuropean Journal of Radiology, 2003
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent.2003
- MRI of the tumor microenvironmentJournal of Magnetic Resonance Imaging, 2002
- HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancerAnnals of Oncology, 2001